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Original Investigation | Cardiology
Association of Inferior Vena Cava Filter Placement
for Venous Thromboembolic Disease and a Contraindication
to AnticoagulationWith 30-DayMortality
Tyson E. Turner, MD, MPH; Mohammed J. Saeed, MBChB, MPH; Eric Novak, MS; David L. Brown, MD
Abstract
IMPORTANCE Despite the absence of data from randomized clinical trials, professional societies
recommend inferior vena cava (IVC) filters for patients with venous thromboembolic disease (VTE)
and a contraindication to anticoagulation therapy. Prior observational studies of IVC filters have
suggested a mortality benefit associated with IVC filter insertion but have often failed to adjust for
immortal time bias, which is the time before IVC filter insertion, during which death can only occur in
the control group.
OBJECTIVE To determine the association of IVC filter placement with 30-daymortality after
adjustment for immortal time bias.
DESIGN, SETTING, ANDPARTICIPANTS This comparative effectiveness, retrospective cohort
study used a population-based sample of hospitalized patients with VTE and a contraindication to
anticoagulation using the State Inpatient Database and the State Emergency Department Database,
part of the Healthcare Cost andUtilization Project of the Agency for Healthcare Research andQuality,
from hospitals in California (January 1, 2005, to December 31, 2011), Florida (January 1, 2005, to
December 31, 2013), and New York (January 1, 2005, to December 31, 2012). Data analysis was
conducted from September 15, 2015, to March 14, 2018.
EXPOSURE Inferior vena cava filter placement.
MAINOUTCOMESANDMEASURES Multivariable Cox proportional hazardmodels were
constructedwith IVC filters as a time-dependent variable that adjusts for immortal time bias. The Cox
model was further adjusted using the propensity score as an adjustment variable.
RESULTS Of 126030 patients with VTE, 61 281 (48.6%) weremale and themean (SD) age was 66.9
(16.6) years. In this cohort, 45 771 (36.3%) were treated with an IVC filter, whereas 80 259 (63.7%)
did not receive a filter. In the Cox model with IVC filter status analyzed as a time-dependent variable
to account for immortal time bias, IVC filter placementwas associatedwith a significantly increased
hazard ratio of 30-day mortality (1.18; 95% CI, 1.13-1.22; P < .001). When the propensity score was
included in the Coxmodel, IVC filter placement remained associatedwith an increased hazard ratio of
30-daymortality (1.18; 95% CI, 1.13-1.22; P < .001).
CONCLUSIONSANDRELEVANCE After adjustment for immortal time bias, IVC filter placement was
associated with increased 30-daymortality in patients with VTE and a contraindication to
anticoagulation. Randomized clinical trials are needed to determine the efficacy of IVC filter
placement in patients with VTE and a contraindication to anticoagulation.
JAMA Network Open. 2018;1(3):e180452. doi:10.1001/jamanetworkopen.2018.0452
Key Points
Question What is the association of
inferior vena cava filter placement with
30-daymortality in patients with venous
thromboembolic disease and a
contraindication to anticoagulation?
Findings In this cohort study, using 2
different statistical methods with
adjustment for immortal time bias,
inferior vena cava filter placement in
patients with venous thromboembolic
disease and a contraindication to
anticoagulation was associated with an
increased risk of 30-daymortality.
Meaning Randomized clinical trials are
needed to define the role of inferior
vena cava filter placement in patients
with venous thromboembolic disease
and a contraindication to
anticoagulation.
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Introduction
Venous thromboembolism (VTE),which includes both pulmonary embolism (PE) anddeep vein throm-
bosis (DVT), is a significant cause ofmorbidity andmortalityworldwide,with an incidence of 117 cases
per 100000person-years1 and a 1-yearmortality for PEof at least 22% inpatientswithMedicare.2
Treatment of patientswithVTE is basedon anticoagulation, but formanypatients, this therapy is con-
traindicated owing to recent surgery or underlying coagulopathies. In patientswithVTE and a contrain-
dication to anticoagulation,major professional societies, including theAmericanCollege of Chest
Physicians,3 AmericanHeart Association,4 Society of Interventional Radiology,5,6 AmericanCollege of
Radiology,7 and theBritish Committee for Standards inHaematology8 recommend consideration of IVC
filter placement.While IVC filters havebeenwidely available since the 1960s, their use in theUnited
States has steadily anddramatically increased from2000procedures in 1979 tomore than 100000
procedures in 2005.9More recently, rates havebegun to declinewith approximately 96000proce-
dures in 2014.10 This use has occurreddespite the absence of data on amortality benefit associated
with IVC filter placement. An early randomized clinical trial showed a reduction in the number of symp-
tomatic PEs but no reduction inmortality after IVC filter insertion. Importantly, this trial excludedpa-
tientswith a contraindication to anticoagulant therapy,11 which is, to our knowledge, themostwidely
accepted indication for IVC filter placement and the only indication forwhich the several professional
societies agree. Retrievable IVC filterswere analyzed in a randomized clinical trial12 of patientswith PE
and ahigh likelihoodof recurrence. In this trial,12 IVC filters did not lower recurrent PE, but patientswith
a contraindication to anticoagulationwere excluded. Thus, the findings of existing randomized clinical
trials are not applicable to a large segment of theVTEpopulation.
As a result, in the last 3 years, observational studies have attempted to understand the
association between IVC filter placement in patients with VTE and a contraindication to
anticoagulation and their outcomes. These studies have often failed to adjust for immortal time bias,
which is the interval between hospital admission and IVC filter placement, during which time death
cannot occur in the intervention group but can occur in the control group.13 Failing to account for this
potential source of bias can erroneously skew the results in favor of the intervention by falsely
conferring a survival advantage to the treated group.13 Given this concern for unaccounted biases in
the context of a relatively common invasive procedure for which there is no evidence of amortality
benefit, we conducted an analysis incorporating adjustment for immortal time bias using 2 different
statistical models to evaluate the outcomes of IVC filter placement in patients with VTE and a
contraindication to anticoagulation.
Methods
This comparative effectiveness, retrospective cohort study used the State Inpatient Database (SID)
and the State Emergency Department Database, a part of the Healthcare Cost and Utilization Project
of the Agency for Healthcare Research and Quality, from hospitals in California (January 1, 2005, to
December 31, 2011), Florida (January 1, 2005, to December 31, 2013), and New York (January 1, 2005,
to December 31, 2012).14,15 This study conformed to the International Society for
Pharmacoeconomics and Outcomes Research (ISPOR) reporting guideline. The SID includes inpatient
discharge records from nonfederal, short-term general hospitals. The SID data sets from California,
Florida, and New York contain an encrypted person identifier allowing longitudinal follow-up. Records
with amissing person identifier and records from psychiatric, dependency, and rehabilitation hospitals
were excluded. Same-day hospital transfers were considered a single hospitalization. Each SID record
contains International Classification of Diseases, Ninth Revision, ClinicalModification (ICD-9-CM) diagnosis
and procedure codes. Diagnosis codes are assigned at discharge without corresponding timing
information and include 1 primary admitting diagnosis code that reflects the principle reason for
hospitalization. Each procedure code has corresponding timing information indicating the day of the
procedure during the hospitalization. The State Emergency Department Database includes records for
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hospital-affiliated emergency department visits not resulting in hospitalization. Emergency department
visits resulting in hospitalization are included in the SID. TheWashington University Human Research
Protection Office granted this study an exemption from institutional review board oversight due to
the deidentified nature of the data set.
Study Population
Adult patients (aged18 years) with inpatient records coded for PE and/or DVTwere identified from
California (2006-2010), Florida (2006-2012), and New York (2006-2011). The earliest
hospitalization of a patient with PE or DVTwas defined as the index hospitalization and was required
to have the preceding 12-month period free of inpatient records coded for PE, DVT, or IVC filter
insertion. Contraindications to anticoagulation were identified by ICD-9-CM diagnosis or procedure
codes and included any of the following: intracranial bleeding, other major bleeding,
thrombocytopenia, active gastrointestinal bleeding, aortic dissection, pericardial disease, bacterial
endocarditis, threatened abortion, preeclampsia and eclampsia, malignant hypertension, brain
surgery, spinal surgery or spinal puncture, and eye surgery coded at the index hospitalization or
within the prior 15 days (Table 1). In addition, hemophilia, vonWillebrand disease, and cerebral
aneurysm coded at the index hospitalization or within the prior year were considered
contraindications to anticoagulation. Index hospitalizations with missing sex, residence outside the
hospital state, and hospitalization length of stay of more than 6months were excluded.
Primary Exposure, Outcomes, andOther Baseline Characteristics
During the index hospitalization, IVC filter insertion was identified by the ICD-9-CM procedure code
38.7. Comorbidities were identified using the Elixhauser classification16 derived from the index
hospitalization and admissions within the preceding year. Medical insurance (Medicare, Medicaid,
private insurance, and other) and admission through the emergency department were identified at
the index hospitalization.
Statistical Analysis
Our primary method of analysis was a multivariable Cox model with IVC filter status as a time-
dependent variable to account for immortal time bias. The start time for this analysis was the date of
index hospitalization. Patients were followed up until the time of an event or censored at 30 days.
Patients with IVC filters were not identified until the time of procedure to allow for a time-dependent
IVC filter status. The following variables were used in themultivariable, time-dependent Coxmodel
and to build a propensity score with a logistic regression model: age, sex, primary payer, admission
through emergency department, thromboembolism, intracranial bleeding, other major bleeding,
thrombocytopenia, active gastrointestinal ulcer, hemophilia or vonWillebrand disease, cerebral
aneurysm, aortic dissection, pericardial disease, bacterial endocarditis, preeclampsia and eclampsia,
malignant hypertension, brain surgery, spinal surgery, eye surgery, congestive heart failure, valvular
disease, pulmonary circulation disease, peripheral vascular disease, paralysis, other neurologic
disorders, chronic obstructive pulmonary disease, diabetes, hypertension, hypothyroidism, renal
failure, liver disease, peptic ulcer disease, lymphoma, metastatic cancer, solid tumors without
metastasis, rheumatoid arthritis, coagulopathy, obesity, weight loss, fluid and electrolyte disorders,
chronic blood loss anemia, alcohol abuse, drug abuse, psychoses, and depression. A second Cox
model was created that included the original variables and the propensity score as an additional
adjustment variable. The follow-up period started at the admission date of the index hospitalization
for individuals with and without IVC filter insertion. The primary outcome of interest was mortality at
30 days. Baseline characteristics of patients with and without IVC filter were compared using
2-sample t test for continuous variables and χ2 test for categorical data. To account for any
overdispersion, the Pearson χ2 test was used to adjust standard errors via quasi-likelihood
estimation. A 2-sided t test was used, and P < .05 was considered statistically significant. All analyses
were conducted using SAS, version 9.3 and SAS Enterprise Guide, version 7.1 (SAS Institute Inc).
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Table 1. ICD-9-CMDiagnosis and Procedure Codes Used to Identify Study Conditions and Procedures
Condition or Procedure ICD-9-CM Codes
Diagnosis
Deep vein thrombosis 45111, 45119, 4512, 45181, 4519, 4533, 45340, 45341, 45342, 4539, 6713x, 6714x, 6719x
Pulmonary embolism 41511, 41512, 41519, 6346x, 6356x, 6366x, 6376x, 6386, 6396, 6732x, 6733x
Intracranial bleeding 430, 431, 432x, 852x, 853x
Other major bleeding 4560, 45620, 5307, 53082, 53100, 53101, 53120, 53121, 53140, 53141, 53160, 53161, 53200, 53201, 53220,
53221, 53240, 53241, 53260, 53261, 53300, 53301, 53320, 53321, 53340, 53341, 53360, 53361, 53400, 53401,
53420, 53421, 53440, 53441, 53460, 53461, 5693, 5780, 5781, 5789, 64000, 64001, 64003, 64080, 64081,
64083, 64090, 64091, 64093, 64100, 64101, 64103, 64110, 64111, 64113, 64120, 64121, 64123, 64130, 64131,
64133, 64180, 64181, 64183, 64190, 64191, 64193, 2463, 2528, 2800, 2851, 2878, 2879, 36361, 36362, 37481,
37632, 37742, 37923, 4590, 53021, 53501, 53511, 53521, 53531, 53541, 53551, 53561, 53571, 56881, 56985,
6021, 6262, 63410, 63411, 63412, 63510, 63511, 63512, 63610, 63611, 63612, 63710, 63711, 63712, 6381,
6391, 66454, 66570, 66571, 66572, 66574, 66600, 66602, 66604, 66610, 66612, 66614, 66620, 66622, 66624,
67430, 67432, 67434, 7725, 7847, 7848, 7863, 9582, 99811, 99812
Active gastrointestinal ulcer 5311x, 5313x, 5315x, 5321x, 5323x, 5325x, 5331x, 5333x, 5335x, 5341x, 5343x, 5345
Hemophilia and von Willebrand disease 2860, 2861, 2862, 2863, 2864
Thrombocytopenia 2873x, 2874, 28984, 2875
Cerebral aneurysm 09487, 4373, 74781
Aortic dissection 4410x
Pericarditis and pericardial effusion 03641, 07421, 09381, 09883, 3910, 393, 420x, 423x
Bacterial endocarditis 03642, 0932x, 09884, 421x
Threatened abortion 6400x
Preeclampsia and eclampsia 6424x, 6425x, 6426x, 6427x
Malignant hypertension 4010, 4020x, 4030x, 4040x, 4050x
Burns 9065, 9066, 9067, 9068, 9069, 9400, 9401, 9402, 9403, 9404, 9405, 9409, 94100, 94101, 94102, 94103, 94104,
94105, 94106, 94107, 94108, 94109, 94110, 94111, 94112, 94113, 94114, 94115, 94116, 94117, 94118, 94119,
94120, 94121, 94122, 94123, 94124, 94125, 94126, 94127, 94128, 94129, 94130, 94131, 94132, 94133, 94134,
94135, 94136, 94137, 94138, 94139, 94140, 94141, 94142, 94143, 94144, 94145, 94146, 94147, 94148, 94149,
94150, 94151, 94152, 94153, 94154, 94155, 94156, 94157, 94158, 94159, 94200, 94201, 94202, 94203, 94204,
94205, 94209, 94210, 94211, 94212, 94213, 94214, 94215, 94219, 94220, 94221, 94222, 94223, 94224, 94225,
94229, 94230, 94231, 94232, 94233, 94234, 94235, 94239, 94240, 94241, 94242, 94243, 94244, 94245, 94249,
94250, 94251, 94252, 94253, 94254, 94255, 94259, 94300, 94301, 94302, 94303, 94304, 94305, 94306, 94309,
94310, 94311, 94312, 94313, 94314, 94315, 94316, 94319, 94320, 94321, 94322, 94323, 94324, 94325, 94326,
94329, 94330, 94331, 94332, 94333, 94334, 94335, 94336, 94339, 94340, 94341, 94342, 94343, 94344, 94345,
94346, 94349, 94350, 94351, 94352, 94353, 94354, 94355, 94356, 94359, 94400, 94401, 94402, 94403, 94404,
94405, 94406, 94407, 94408, 94410, 94411, 94412, 94413, 94414, 94415, 94416, 94417, 94418, 94420, 94421,
94422, 94423, 94424, 94425, 94426, 94427, 94428, 94430, 94431, 94432, 94433, 94434, 94435, 94436, 94437,
94438, 94440, 94441, 94442, 94443, 94444, 94445, 94446, 94447, 94448, 94450, 94451, 94452, 94453, 94454,
94455, 94456, 94457, 94458, 94500, 94501, 94502, 94503, 94504, 94505, 94506, 94509, 94510, 94511, 94512,
94513, 94514, 94515, 94516, 94519, 94520, 94521, 94522, 94523, 94524, 94525, 94526, 94529, 94530, 94531,
94532, 94533, 94534, 94535, 94536, 94539, 94540, 94541, 94542, 94543, 94544, 94545, 94546, 94549, 94550,
94551, 94552, 94553, 94554, 94555, 94556, 94559, 9460, 9461, 9462, 9463, 9464, 9465, 9470, 9471, 9472,
9473, 9474, 9478, 9479, 94800, 94810, 94811, 94820, 94821, 94822, 94830, 94831, 94832, 94833, 94840,
94841, 94842, 94843, 94844, 94850, 94851, 94852, 94853, 94854, 94855, 94860, 94861, 94862, 94863, 94864,
94865, 94866, 94870, 94871, 94872, 94873, 94874, 94875, 94876, 94877, 94880, 94881, 94882, 94883, 94884,
94885, 94886, 94887, 94888, 94890, 94891, 94892, 94893, 94894, 94895, 94896, 94897, 94898, 94899, 9490,
9491, 9492, 9493, 9494, 9495
Trauma 800-839, 850-904, 925-939, 950-957, 990-994
Surgical procedure
Brain surgery 0112, 0114, 0120, 0121, 0122, 0123, 0124, 0125, 0128, 0129, 0131, 0132, 0139, 0141, 0142, 0151, 0152, 0153,
0159, 0211, 0212, 0213, 0214, 0291, 0292, 0293, 0751, 0752, 0753, 0754, 0759, 0761, 0762, 0763, 0764, 0765,
0768, 0769, 0771, 0772, 0779, 3801, 3811, 3831, 3841, 3851, 3861, 3881, 3928
Spine surgery 810x, 813x, 0301, 0302, 0309, 8050, 8051, 8053, 8054, 8059, 8460, 8461, 8462, 8463, 8464, 8465, 8466, 8467,
8468, 8469, 8480, 8481, 8482, 8483, 8484, 8485, 8161, 8162, 8163, 8164, 8451, 0332, 0339, 034
Eye surgery 1160, 1161, 1162, 1163, 1164, 1169, 1251, 1252, 1253, 1254, 1255, 1259, 1261, 1262, 1263, 1264, 1265, 1266,
1267, 1269, 1271, 1272, 1273, 1274, 1279, 1311, 1319, 132, 133, 1341, 1342, 1343, 1351, 1359, 1361, 1362,
1363, 1364, 1365, 1366, 1369, 1370, 1371, 1372, 138, 139, 1390, 1391, 1431, 1432, 1433, 1434, 1435, 1439,
1441, 1449, 1451, 1452, 1453, 1454, 1455, 1459, 1421, 1422, 1423, 1424, 1425, 1426, 1427, 1429, 1200, 1201,
1202, 1211, 1212, 1213, 1214, 1231, 1232, 1233, 1234, 1235, 1239, 1240, 1241, 1242, 1243, 1244, 1281, 1282,
1283, 1284, 1285, 1286, 1287, 1288, 1289, 1291, 1292, 1293, 1297, 1298, 1299, 1300, 1301, 1302, 1400, 1401,
1402, 146, 1471, 1472, 1473, 1474, 1475, 1479, 1481, 1482, 1483, 149
Spinal puncture 0331, 8721
Embolectomy and thrombectomy or endarterectomy
of thoracic vessels (other than aorta)
3805, 3815
Hip replacement 0070, 0071, 0072, 0073, 0085, 0086, 0087, 8151, 8152, 8153
Knee replacement 0080, 0081, 0082, 0083, 0084, 8154, 8155
Abbreviation: ICD-9-CM, International Classification of Diseases, Ninth Revision, Clinical Modification.
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Results
We identified 132 355 patients 18 years and older with an ICD-9-CM hospitalization code for PE, DVT,
or both along with a contraindication to anticoagulation from California (2006-2010), Florida
(2006-2012), and New York (2006-2011). After application of exclusion criteria, 126 124 patients
remained in the study. Of these, 94 patients with IVC filter had incomplete data for analysis, leaving
126030 patients in the final study population (Figure), with 45 771 (36.3%) receiving an IVC filter
and 80 259 (63.7%) who did not receive an IVC filter. Baseline characteristics and coexisting
conditions are presented in Table 2. Of the 126030 patients, 61 281 (48.6%) weremale and the
mean (SD) age was 66.9 (16.6) years. Themedian time to IVC filter placement was 5.0 days
(interquartile range, 2.0-11.0 days).
When evaluated in a multivariable Cox model with IVC filter placement analyzed as a time-
dependent variable to account for immortal time bias, IVC filter placement was associated with an
increased hazard ratio of mortality (1.18; 95% CI, 1.13-1.22; P < .001). After the addition of the
propensity score to themultivariable Coxmodel, IVC filter placement continued to be associated
with an increased hazard ratio of mortality (1.18; 95% CI, 1.13-1.22; P < .001).
Discussion
Themost significant finding of this study of IVC filter use in patients with VTE and a contraindication
to anticoagulation is that treatment with an IVC filter was associatedwith a higher 30-daymortality
than treatment without IVC filter placement after adjustment for demographics, comorbidities,
immortal times bias, and the propensity to receive a filter.
The initial long-term evaluation of IVC filter use was by Greenfield et al in 198117 and was
expanded in the late 1980s18 to include 469 patients. This study showed a 4% rate of PE in patients
after placement of an IVC filter but had suboptimal follow-up and lacked a control group. Largely
based on this work, IVC filter implantation increased from 2000 procedures in 1979 tomore than
100000 in 2005.9 At present, there are 2 randomized clinical trials evaluating the long-term
outcomes of IVC filter use. The first, originally published in 199811 with a follow-up report in 2005,19
found that patients with VTE who were randomized to receive IVC filters experienced a reduction in
symptomatic PE, no change inmortality, and an increased risk of recurrent DVT. Importantly, this trial
excluded patients with a contraindication to anticoagulation, negating its applicability to the subset
of patients in whom IVC filters are most universally recommended. The second study,12 published in
2015, randomized 399 patients with PE and a high probability of recurrence to anticoagulation and
a retrievable IVC filter vs anticoagulation alone. The outcomes of the 2 groups did not differ with
respect to the primary outcome of recurrent PE or secondary outcomes including death or DVT at 3
Figure. Derivation of the Study Population
126 030 Study population
132 355 Participants aged ≥18 y; no
missing person identifier;
hospitalization with ICD-9-CM
diagnosis code for PE, DVT,
or both; contraindication to
anticoagulation; in California
(2006-2010), Florida
(2006-2012), or New York
(2006-2011)
6325 Excluded
599 Hospitalization in prior y with IVC filter
41 Missing sex
4942 Residence outside the hospital state
649 Index hospitalization >6 mo
94 Incomplete IVC filter date and time
variable DVT indicates deep venous thrombosis;
ICD-9-CM, International Classification of Diseases,
Ninth Revision, Clinical Modification; IVC, inferior vena
cava; PE, pulmonary embolism.
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Table 2. Patient Characteristics
Characteristics
No. (%)
Overall (n = 126 030) No IVC Filter (n = 80 259) IVC Filter (n = 45 771)
Male 61 281 (48.6) 38 673 (48.2) 22 608 (49.4)
Age at admission, mean (SD), y 66.9 (16.6) 65.7 (17.1) 69.1 (15.6)
Primary expected payer
Medicare 76 383 (60.6) 47 036 (58.6) 29 347 (64.1)
Medicaid 12 654 (10.0) 8500 (10.6) 4154 (9.1)
Private insurance 29 011 (23.0) 19 070 (23.8) 9941 (21.7)
Self-pay 3289 (2.6) 2405 (3.0) 884 (1.9)
No charge 743 (0.6) 548 (0.7) 195 (0.4)
Other 3950 (3.1) 2700 (3.4) 1250 (2.7)
Payment method
Government insurance 89 037 (70.6) 55 536 (69.2) 33 501 (73.2)
Private insurance 29 011 (23.0) 19 070 (23.8) 9941 (21.7)
Other 7982 (6.3) 5653 (7.0) 2329 (5.1)
ED visit 99 818 (79.2) 62 770 (78.2) 37 048 (80.9)
Thromboembolism
PE and DVT 19 271 (15.3) 9263 (11.5) 10 008 (21.9)
PE only 42 398 (33.6) 32 447 (40.4) 9951 (21.7)
DVT only 64 361 (51.1) 38 549 (48.0) 25 812 (56.4)
Intracranial bleeding 9691 (7.7) 3574 (4.5) 6117 (13.4)
Other major bleeding 71 455 (56.7) 43 216 (53.8) 28 239 (61.7)
Thrombocytopenia 37 624 (29.9) 25 743 (32.1) 11 881 (26.0)
Active gastrointestinal ulcer 704 (0.6) 434 (0.5) 270 (0.6)
Hemophilia or von Villebrand
disease
374 (0.3) 210 (0.3) 164 (0.4)
Cerebral aneurysm 448 (0.4) 197 (0.2) 251 (0.5)
Aortic dissection 833 (0.7) 575 (0.7) 258 (0.6)
Pericardial disease 6121 (4.9) 4583 (5.7) 1538 (3.4)
Endocarditis 3857 (3.1) 3448 (4.3) 409 (0.9)
Preeclampsia and eclampsia 111 (0.1) 96 (0.1) 15 (0.0)
Malignant hypertension 3342 (2.7) 2468 (3.1) 874 (1.9)
Cranial surgery 5124 (4.1) 1723 (2.1) 3401 (7.4)
Spinal surgery 6331 (5.0) 3651 (4.5) 2680 (5.9)
Recent lumbar puncture 5224 (4.1) 3628 (4.5) 1596 (3.5)
Eye surgery 91 (0.1) 73 (0.1) 18 (0.0)
Congestive heart failure 33 850 (26.9) 21 612 (26.9) 12 238 (26.7)
Valvular disease 17 974 (14.3) 11 901 (14.8) 6073 (13.3)
Diseases of pulmonary vasculature 65 822 (52.2) 44 343 (55.2) 21 479 (46.9)
Peripheral vascular disease 17 954 (14.2) 11 576 (14.4) 6378 (13.9)
Paralysis 12 998 (10.3) 6522 (8.1) 6466 (14.1)
Other neurological disorders 23 289 (18.5) 12 978 (16.2) 10 311 (22.5)
Chronic obstructive pulmonary
disease
37 618 (29.8) 24 210 (30.2) 13 408 (29.3)
Diabetes 37 830 (30.0) 23 617 (29.4) 14 213 (31.1)
Hypertension 87 354 (69.3) 54 783 (68.3) 32 571 (71.2)
Hypothyroidism 17 839 (14.2) 11 245 (14.0) 6594 (14.4)
Renal failure 28 916 (22.9) 18 355 (22.9) 10 561 (23.1)
Liver disease 7932 (6.3) 5136 (6.4) 2796 (6.1)
Peptic ulcer disease 67 625 (53.7) 42 733 (53.2) 24 892 (54.4)
Lymphoma 3788 (3.0) 2372 (3.0) 1416 (3.1)
Metastatic cancer 17 018 (13.5) 9777 (12.2) 7241 (15.8)
Solid tumor without metastasis 24 647 (19.6) 14 035 (17.5) 10 612 (23.2)
(continued)
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or 6months. Because both groups had anticoagulation, patients with a contraindication to
anticoagulation were excluded. In contrast, our study evaluates a diverse patient population with
multiple contraindications to anticoagulation and not only extends the findings of prior IVC filter
publications but also adjusts for the effect of immortal time in observational studies to bias results in
favor of intervention.
Given the widespread use of IVC filters and persistent questions regarding their efficacy, several
observational studies within the last 5 years have attempted to further evaluate the association of
IVC filter use andmortality.2,20-22 These studies, which involved different subgroups of patients with
VTE having varying ability to tolerate anticoagulation, were similar in that none of them adjusted for
immortal time bias. In contrast, a 2016 study23 did attempt to address the issue of immortal time bias
in the assessment of IVC filter efficacy. This study retrospectively analyzed patients without cancer
in California with acute VTE and included both patients who could tolerate anticoagulation and those
with a contraindication. The only group of patients in whom IVC filter use significantly reduced the
short-term risk of death was the approximately 3000-patient subset with acute VTE and a
contraindication to anticoagulation owing to active bleeding. Referring an actively bleeding patient
for an invasive procedure is likely to involve selection bias whereby the sickest patients are
considered too high risk for the procedure and are relegated to the control group, thus possibly
confounding the results. This study attempts to expand on these findings by analyzing a diverse
patient cohort includingmultiple states, patients with cancer, patients with a contraindication to
anticoagulation, and patients who are and are not actively bleeding.
Limitations
Our findings should be interpreted within the context of several limitations. This study is
retrospective and uses observational data derived from codes designed for reimbursement. A 2016
study proposed that the use of diagnostic codes from claims data can lead to an underestimation of
event rates.24 Furthermore, retrospective observational studies may be subject to various types of
bias that persist despite various techniques to adjust for differences in baseline characteristics.
Therefore, these results should be considered hypothesis generating only. Second, this study only
captured patient deaths during the index hospitalization, on a repeated admission or at a subsequent
emergency department visit in the same state as the index hospitalization, thereby allowing for the
possibility that some out-of-hospital or out-of-state deaths were not captured. However, there is no
reason to believe these uncaptured events would occur more frequently in one group than in the
other. Third, contraindications to anticoagulation span a range fromminor relative contraindications
to severe absolute contraindications. The lack of granularity of administrative data precludes the
determination of the degree of absoluteness of any patient’s contraindication to anticoagulation,
whether therapeutic anticoagulation was attempted but required discontinuation, or if a patient was
Table 2. Patient Characteristics (continued)
Characteristics
No. (%)
Overall (n = 126 030) No IVC Filter (n = 80 259) IVC Filter (n = 45 771)
Rheumatoid arthritis and/or
collagen vascular disease
5854 (4.6) 3824 (4.8) 2030 (4.4)
Coagulopathy 44 212 (35.1) 29 535 (36.8) 14 677 (32.1)
Obesity 20 793 (16.5) 13 631 (17.0) 7162 (15.6)
Recent weight loss 22 412 (17.8) 13 223 (16.5) 9189 (20.1)
Fluid and electrolyte disorders 70 232 (55.7) 42 924 (53.5) 27 308 (59.7)
Chronic blood loss anemia 15 152 (12.0) 8671 (10.8) 6481 (14.2)
Deficiency anemias 57 670 (45.8) 36 132 (45.0) 21 538 (47.1)
Alcohol abuse 8039 (6.4) 5089 (6.3) 2950 (6.4)
Drug abuse 5889 (4.7) 4465 (5.6) 1424 (3.1)
Psychoses 8950 (7.1) 5614 (7.0) 3336 (7.3)
Depression 19 382 (15.4) 12 312 (15.3) 7070 (15.4)
Abbreviations: DVT, deep venous thrombosis;
ED, emergency department; IVC, inferior vena cava;
PE, pulmonary embolism.
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a suitable candidate for an IVC filter. Fourth, we are unable to determine whether the IVC filters used
were retrievable and whether they were ever retrieved.
Conclusions
This analysis suggests that patients with a contraindication to anticoagulation who receive an IVC
filter have an increased risk of death at 30 days after adjustment for baseline differences,
comorbidities, immortal time bias, and propensity score compared with similar patients who did not
receive an IVC filter. Randomized clinical trials are required to determine the efficacy of IVC filter
placement in patients with VTE and a contraindication to anticoagulation.
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